Histogen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Meeting adjourned for a final time to january 4, 2024 at 8:00 a.m. pt potential estimated cash distribution to shareholders of $0.30 to $0.41 if dissolution proposal approved

San diego, dec. 05, 2023 (globe newswire) -- histogen inc. (otc: hsto) today announced that its special meeting of stockholders (the “special meeting”) has been adjourned to thursday, december 14, 2023 at 8:00 a.m. pacific time with respect to both proposals described in its definitive proxy statement filed with the u.s. securities and exchange commission (the “sec”) on october 18, 2023 (the “proxy statement”).

San diego, sept. 18, 2023 (globe newswire) -- histogen inc. (nasdaq: hsto), today announced that its board of directors, after extensive consideration of potential strategic alternatives, has approved and adopted a plan of dissolution (“plan of dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. in order to reduce costs and in connection with the plan of dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of september.

Mclean, va.--(business wire)--amerimmune llc is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including covid-19. amerimmune llc had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of covid19 patients. caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system. the scientists at amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with covid-19. a drug that blocks the caspase molecules would potentially prevent disease progression in covid19. after evaluating a number of potential candidates, amerimmune llc identified emricasan as a drug that could be used to prevent disease progression...

San diego, may 17, 2022 (globe newswire) -- histogen inc. (nasdaq: hsto), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that steven j. mento, ph.d., histogen's executive chairman and interim president and chief executive officer, will present at the h.c. wainwright global investment conference.

Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.

Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen's Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.